Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies

Blood (2024) 143 (14): 1414–1424.

https://doi.org/10.1182/blood.2023022457

Published: 2024

Includes: Supplemental data

Journal Articles

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Marissa J.M. Traets, Sigrid van der Veen, Jennifer Bos, Laura van Pelt, Aida Kidane, Brigitte A. van Oirschot, Wouter W. van Solinge, Saskia Schols, Mandy N. Lauw, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Eduard J. Van Beers, Anita W. Rijneveld, Richard van Wijk, Minke A.E. Rab

Blood (2023) 142 (Supplement 1): 561.

https://doi.org/10.1182/blood-2023-180755

Published: 2023

Journal Articles

National Long-Term Follow-up of Children with Sickle Cell Disease Diagnosed By Newborn Screening in the Netherlands: Overview of the Morbidity and Mortality

Caroline Vuong, Cornelia De Groot - Eckhardt, Harriët Heijboer, Monique H. Suijker, Lydian A. De Ligt, Marije Bartels, Paul Brons, Louise Hooimeijer, Eva Rettenbacher, Frans J. Smiers, Marjet A. Stein-Wit, Arian van der Veer, Annemieke Verbaan, Marjon H. Cnossen, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 3891.

https://doi.org/10.1182/blood-2023-179802

Published: 2023

Journal Articles

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Myrthe J. van Dijk, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers

Blood (2023) 142 (Supplement 1): 2515.

https://doi.org/10.1182/blood-2023-172829

Published: 2023

Journal Articles

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Myrthe J. van Dijk, Sigrid van der Veen, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Richard van Wijk, Eduard J. van Beers

Blood (2022) 140 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2022-155997

Published: 2022

Journal Articles

Long-Term Follow-up of Dutch Patients with Sickle Cell Disease Diagnosed By Newborn Screening - Effect on the Morbidity and Mortality in the Netherlands

Caroline Vuong, Corien L. Eckhardt, Lydian de Ligt, Harriet Heijboer, Eva Rettenbacher, Arian van der Veer, Marjet Stein-Wit, Paul Brons, Frans J. Smiers, Monique Suijker, Marjon H. Cnossen, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 2562–2563.

https://doi.org/10.1182/blood-2022-163100

Published: 2022

Journal Articles

Low Von Willebrand Factor: Cut-Off Value for Diagnosis and Risk Score to Predict Bleeding Incidence

Ferdows Atiq, Esmee Wuijster, BSc, Moniek P.M. de Maat, PhD, Marieke J.H.A. Kruip, MD PhD, Marjon H. Cnossen, MD PhD, Frank W.G. Leebeek, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-142375

Published: 2020

Journal Articles

Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease

Ferdows Atiq, Johan Boender, MD, Marjon H. Cnossen, MD PhD, Johanna G van der Bom, MD PhD, Karin Fijnvandraat, MD PhD, Joke de Meris, Moniek P.M. de Maat, PhD, Karin P.M. Van Galen, MD MSc, PhD, Britta A.P. Laros-Van Gorkom, MD PhD, Karina Meijer, MD PhD, Jeroen C.J. Eikenboom, MD PhD, Frank W.G. Leebeek, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142287

Published: 2020

Journal Articles

Oxygen Gradient Ektacytometry-Derived Biomarkers Are Associated with the Occurrence of Cerebral Infarction, Acute Chest Syndrome and Vaso-Occlusive Crisis in Sickle Cell Disease

Minke A.E. Rab, MD, Celeste K. Kanne, BA, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, MD, Celine Renoux, PhD, Marije Bartels, MD PhD, Erfan Nur, MDPhD, Marjon H. Cnossen, MD PhD, Philippe Joly, PhD, Romain Fort, MD, Philippe Connes, PhD, Richard van Wijk, PhD, Vivien A. Sheehan, MD PhD, Eduard van Beers, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-135934

Published: 2020

Journal Articles

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Minke A.E. Rab, MD, Richard van Wijk, PhD, Celeste K. Kanne, BA, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, MD, Jorn J. Gerritsma, MD, Karin Fijnvandraat, MD PhD, Celine Renoux, PhD, Marije Bartels, MD PhD, Erfan Nur, MD PhD, Marjon H. Cnossen, MD PhD, Philippe Joly, PhD, Romain Fort, MD, Philippe Connes, PhD, Eduard J. van Beers, MD PhD, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 2275.

https://doi.org/10.1182/blood-2019-128870

Published: 2019

Journal Articles

Health Literacy, Self-Efficacy and Knowledge of Sickle Cell Disease Among Caregivers

Maite E. Houwing, MD, Rowena Grohssteiner, BSc, Sonja A.M.C. Teuben, Jan A Hazelzet, MD PhD, Anne P.J. de Pagter, MD PhD, Mirjam P. Fransen, Marjon H. Cnossen, MD PhD

Blood (2019) 134 (Supplement_1): 4841.

https://doi.org/10.1182/blood-2019-129888

Published: 2019

Journal Articles

Improving Access to Healthcare for Pediatric Sickle Cell Disease Patients and Their Families

Maite E. Houwing, MD, Marit Buddenbaum, MA, LLM, Thijs C.J. Verheul, BSc, Anne P.J. de Pagter, MD PhD, Jan A Hazelzet, MD PhD, Marjon H. Cnossen, MD PhD

Blood (2019) 134 (Supplement_1): 4835.

https://doi.org/10.1182/blood-2019-129892

Published: 2019

Journal Articles

The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease

Maite E. Houwing, MD, Frederick Thielen, Anne P.J. de Pagter, MD PhD, Jan A Hazelzet, MD PhD, Hedwig Blommestein, Carin A. Uyl-de Groot, Marjon H. Cnossen, MD PhD

Blood (2019) 134 (Supplement_1): 1030.

https://doi.org/10.1182/blood-2019-130372

Published: 2019

Journal Articles

Silent Cerebral Infarcts in Sickle Cell Disease: A Systematic Review

Maite E. Houwing, MD, Rowena Grohssteiner, BSc, Anne P.J. de Pagter, MD PhD, Karin Fijnvandraat, MD PhD, Jaap Oosterlaan, Lotte Haverman, Marjolein Dremmen, Tonya White, Marjon H. Cnossen, MD PhD

Blood (2019) 134 (Supplement_1): 4836.

https://doi.org/10.1182/blood-2019-130165

Published: 2019

Journal Articles

The Oxygenscan: A Rapid and Reproducible Test to Determine Patient-Specific, Clinically Relevant Biomarkers of Disease Severity in Sickle Cell Anemia

Minke A.E, Rab, MD, Celeste K Kanne, BA, Brigitte A. van Oirschot, Jennifer F. Bos, Maite Elizabeth Houwing, MD, Marjon H. Cnossen, MD PhD, Roger Schutgens, MD PhD MSc, Gerard Pasterkamp, MD PhD, Richard van Wijk, PhD, Vivien A Sheehan, MD PhD, Eduard J. van Beers, MD PhD

Blood (2018) 132 (Supplement 1): 2360.

https://doi.org/10.1182/blood-2018-99-112930

Published: 2018

Journal Articles

Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies

Lisette M. Schütte, MD MSc, Nils de Rooij, BSc, Hendrika C.A.M. Hazendonk, MD MSc, Ron A.A. Mathôt, PharmD, PhD, Reinier M. van Hest, PharmD, PhD, Frank W.G. Leebeek, MD PhD, Marjon H. Cnossen, MD PhD, Marieke J.H.A. Kruip, MD PhD

Blood (2015) 126 (23): 3510.

https://doi.org/10.1182/blood.V126.23.3510.3510

Published: 2015

Journal Articles

Value-Based Health Care (VBHC) in Sickle Cell Disease: A Dutch Initiative

Fia ten Brink, MD, Anita W. Rijneveld, MD PhD, Marie-José J.A.G. Claessen, MD, Amando J. Heesterman, Thea J. van Zon, Sonja A.M.C. Teuben, Cora J.D. Onna Van - Walraven, Alice M.A. Goncalves Silva, Francis van Veelen, Renée du Mortier, Marieke A.M.S. Joosten, MD PhD, Fred Petrij, MD PhD, Jan A. Hazelzet, MD PhD, Marjon H. Cnossen, MD PhD

Blood (2015) 126 (23): 5572.

https://doi.org/10.1182/blood.V126.23.5572.5572

Published: 2015

Journal Articles

von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease

Yvonne V. Sanders, Dafna Groeneveld, Karina Meijer, Karin Fijnvandraat, Marjon H. Cnossen, Johanna G. van der Bom, M. Coppens, Joke de Meris, Britta A. P. Laros-van Gorkom, Eveline P. Mauser-Bunschoten, Frank W. G. Leebeek, Jeroen Eikenboom, the WiN study group

Blood (2015) 125 (19): 3006–3013.

https://doi.org/10.1182/blood-2014-09-603241

Published: 2015

Includes: Supplemental data

Journal Articles

Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: “Tackling a Moving Target” (“OPTI-CLOT” Studies)

Janske Lock, MD PhDstudent, Hendrika C.A.M. Hazendonk, MD PhDstudent, Ron A.A. Mathôt, Prof. Dr., Karina Meijer, MD PhD, Marjolein Peters, MD PhD, Paul Brons, Felix J.M. Van der Meer, MD PhD, Hannan Bouzariouh, MD, Mariette H.E. Driessens, PhD, Karin Fijnvandraat, MD PhD, Frank W.G. Leebeek, MD PhD, Marjon H. Cnossen, MD PhD

Blood (2014) 124 (21): 5031.

https://doi.org/10.1182/blood.V124.21.5031.5031

Published: 2014

Journal Articles

Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Do’s and Don’ts after Discrete Choice Experiment Analysis

Janske Lock, MD PhDstudent, Esther W. de Bekker-Grob, PhD, Gamze Urhan, MD, Saskia Middeldorp, MD PhD, Marjolein Peters, MD PhD, Karina Meijer, MD PhD, Rienk Y.J. Tamminga, MD PhD, Britta Laros-van Gorkum, MD PhD, Paul Brons, Felix J.M. Van der Meer, MD PhD, Mariette H.E. Driessens, PhD, Peter W. Collins, MD, Karin Fijnvandraat, MD PhD, Frank W.G. Leebeek, MD PhD, Marjon H. Cnossen, MD PhD

Blood (2014) 124 (21): 5038.

https://doi.org/10.1182/blood.V124.21.5038.5038

Published: 2014

NARROW

Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

National Long-Term Follow-up of Children with Sickle Cell Disease Diagnosed By Newborn Screening in the Netherlands: Overview of the Morbidity and Mortality

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Long-Term Follow-up of Dutch Patients with Sickle Cell Disease Diagnosed By Newborn Screening - Effect on the Morbidity and Mortality in the Netherlands

Low Von Willebrand Factor: Cut-Off Value for Diagnosis and Risk Score to Predict Bleeding Incidence

Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease

Oxygen Gradient Ektacytometry-Derived Biomarkers Are Associated with the Occurrence of Cerebral Infarction, Acute Chest Syndrome and Vaso-Occlusive Crisis in Sickle Cell Disease

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Health Literacy, Self-Efficacy and Knowledge of Sickle Cell Disease Among Caregivers

Improving Access to Healthcare for Pediatric Sickle Cell Disease Patients and Their Families

The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease

Silent Cerebral Infarcts in Sickle Cell Disease: A Systematic Review

The Oxygenscan: A Rapid and Reproducible Test to Determine Patient-Specific, Clinically Relevant Biomarkers of Disease Severity in Sickle Cell Anemia

Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies

Value-Based Health Care (VBHC) in Sickle Cell Disease: A Dutch Initiative

von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease

Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: “Tackling a Moving Target” (“OPTI-CLOT” Studies)

Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Do’s and Don’ts after Discrete Choice Experiment Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only